PMC7071810_01
Clinical time course for a non-small-cell lung cancer patient treated with trastuzumab. The time course for disease and treatment and the results of performed genetic testing are shown starting from the time of diagnosis. Abbreviations: NGS: next-generation sequencing; WBRT: whole brain radiotherapy.
CRIONM2020-9072173.001.jpg
PMC7071810_01_CRIONM2020-9072173.001.jpg
fig1
The time course of his disease starting from diagnosis and his treatment is displayed in Figure 1.
Copy number profile of non-small-cell lung cancer tumor sample identifies ERBB2 amplification as a potentially actionable alteration. A tumor sample from the patient's lung was used to perform comprehensive genomic profiling. The resulting copy number profile is shown, with observed copy numbers being displayed on the y-axis. The red circle indicates the amplification of a genomic region that includes the ERBB2 gene.
CRIONM2020-9072173.002.jpg
PMC7071810_01_CRIONM2020-9072173.002.jpg
fig2
This amplification included CDK12, PGAP3, and the clinically relevant gene ERBB2 (Figure 2). The observed copy numbers for those genes were 11.5, 15, and 15, respectively.
Lung imaging results during the course of the disease. Chest CT imaging is shown for the time between October 2016 and October 2017. For the October 2016 CT image, the lesion is indicated by an arrow.
CRIONM2020-9072173.003.jpg
PMC7071810_01_CRIONM2020-9072173.003.jpg
fig3
CT imaging in June 2017 demonstrated a necrotic regression of the right upper lobe lung lesion after the initiation of trastuzumab treatment (Figure 3).